These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16356991)

  • 21. New NSAIDs and gastroduodenal damage.
    Folco GC
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():28-9. PubMed ID: 9032579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Risk of anastomotic leakage in postoperative treatment with non-steroidal anti-inflammatory drugs].
    Klein M; Gögenur I; Rosenberg J
    Ugeskr Laeger; 2010 May; 172(22):1660-2. PubMed ID: 20525462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.
    Battistella M; Mamdami MM; Juurlink DN; Rabeneck L; Laupacis A
    Arch Intern Med; 2005 Jan; 165(2):189-92. PubMed ID: 15668365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erectile dysfunction induced probably by celecoxib.
    Dhikav V; Gupta S; Anand KS
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):211-2. PubMed ID: 18236511
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: how strong is the evidence?
    Bannwarth BG
    BMJ; 2005 Dec; 331(7530):1474. PubMed ID: 16356999
    [No Abstract]   [Full Text] [Related]  

  • 29. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
    Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A critical evaluation of side effect data on COX-2 inhibitors].
    Pomp E
    Tidsskr Nor Laegeforen; 2002 Feb; 122(5):476-80. PubMed ID: 11961974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

  • 32. Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis.
    Stover RR
    BMJ; 2002 Jul; 325(7356):161; author reply 161. PubMed ID: 12134855
    [No Abstract]   [Full Text] [Related]  

  • 33. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
    White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
    Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Celecoxib and rofecoxib.
    Brinker AD; Bonnel RA; Feight AG; Nourjah P
    J Am Dent Assoc; 2001 Nov; 132(11):1502, 1504. PubMed ID: 11806062
    [No Abstract]   [Full Text] [Related]  

  • 35. [Selective cyclooxygenase-2 inhibitors and the digestive tract].
    Chaabouni H; Amouri A; Cheikh I; Kchaou M; Ouerghi H; Ben Mami N; Ben Ammar A
    Tunis Med; 2002 Aug; 80(8):427-33. PubMed ID: 12703120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study.
    Nørgård B; Pedersen L; Johnsen SP; Tarone RE; McLaughlin JK; Friis S; Sørensen HT
    Aliment Pharmacol Ther; 2004 Apr; 19(7):817-25. PubMed ID: 15043523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
    Goldstein JL; Silverstein FE; Agrawal NM; Hubbard RC; Kaiser J; Maurath CJ; Verburg KM; Geis GS
    Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclooxygenase (COX-2) selective inhibitors. Any better than NSAIDs?
    Nguyen A; Chaiton A
    Can Fam Physician; 2001 Jul; 47():1398-400. PubMed ID: 11494927
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.